Physician profile
David Mccormick
NPI 1336119205
$4,582.85
in general payments reported to CMS, 2019-2025
42 companies · $231 in 2025
The $231 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $982 · 2020: $285 · 2021: $844 · 2022: $882 · 2023: $768 · 2024: $591 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,589.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $859.23 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $631.81 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $521.15 | 2019-2024 | Repatha, Otezla, Prolia |
| Pfizer INC. | $383.22 | 2019-2025 | |
| Abbott Laboratories | $221.86 | 2019-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $213.48 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $201.68 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.45 | 2019-2022 | |
| Novo Nordisk INC | $164.60 | 2019-2023 | Wegovy |
| Janssen Pharmaceuticals, INC | $116.11 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $95.17 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $88.83 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.78 | 2019-2024 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $62.23 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.70 | 2020-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mccormick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.